211 results about "Lipid composition" patented technology

The invention relates to a dialkyl imidazole bionic lipid compound and a preparation method and application thereof.The structure of the dialkyl imidazole bionic lipid compound imitates natural phospholipid design, alkyl with no less than 10 carbon atoms is modified on the fourth site and the fifth site of imidazole, and primary amines with different alkyl chain lengths are modified on the second site; the dialkyl imidazole bionic lipid compound is mixed with a therapeutic drug and other auxiliary materials to prepare lipid nanoparticles loaded with the therapeutic drug, and the lipid nanoparticles can be used as a drug delivery system for preparation of brain-targeted drugs. The dialkyl imidazole bionic lipid has the function of dynamically regulating and controlling the blood-brain barrier, and can realize reversible opening of the blood-brain barrier; the formed drug-loaded lipid composition can pass through a blood brain barrier and well realize brain-targeted delivery of loaded therapeutic drugs; the drug-loaded lipid composition composed of the dialkyl imidazole bionic lipid belongs to a new generation of bionic nano-drug carriers, and provides a new strategy for realizing brain-targeted delivery of different types of drugs.

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.

The purpose of the present invention is to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem / progenitor cell or a mesenchymal stem cell, and a method for delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule wherein the lipid nanoparticle comprises an ionizable lipid and the targeting molecule specifically binds to a marker of hematopoietic stem / progenitor cells or mesenchymal stem cells.

Provided herein are ionizable cationic lipids and lipid nanoparticle compositions comprising a lipid component comprising the same. Also, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering an effective amount of the lipid nanoparticle composition disclosed herein.

The invention relates to the technical field of cosmetics, and discloses an anti-inflammatory soothing cosmetic composition which comprises the following components in percentage by weight: 0.5%-4% of a barrier repairing component, 0.5%-3% of an immunoregulation component, 0.3%-2.5% of a nerve soothing component, 0.3%-3% of an anti-inflammatory plant compound, 1%-10% of a moisturizing soothing enhancer and the balance of auxiliary materials. According to the components, through a five-dimensional synergistic mechanism of barrier repair, immune tolerance, nerve desensitization, anti-inflammatory itching relieving, moisturizing and stability maintaining, anti-inflammatory relieving and barrier repair are remarkably enhanced; ceramide, rare ginsenoside, phytosterol ester and free fatty acid are introduced to synergistically construct a bionic liposome which is closer to the composition of human cuticle lipid, so that the transdermal absorption and stability are enhanced, and the repair efficiency is remarkably improved; the dipotassium glycyrrhizinate, the tamarix chinensis flower extract, the purslane extract, the dinoflaxanthine and the baicalin cooperate to quickly resist inflammation and relieve itching and strengthen barrier repair, so that the composition is suitable for highly sensitive skin.

Provided are a cationic lipid and a preparation method thereof, a lipid composition containing the cationic lipid, and an LNP-drug composition and a preparation thereof containing the lipid composition, especially an LNP-drug composition and a preparation thereof containing the cationic lipid, which have the characteristics of high delivery efficiency and high biocompatibility, thereby improving the therapeutic effect and preventive effect of the drug. The structure of the cationic lipid is shown in general formula (1), and the definitions of the symbols in the formula are as described in the text.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

This disclosure provides a lipid composition and methods of use thereof.

Novel ionizable lipids, compositions, and methods of using the novel lipids and compositions are disclosed. Lipid nanoparticle compositions include novel lipids as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticle compositions further including biologically active agents such as mRNA are useful in the delivery of therapeutics, diagnostics and / or prophylactics to cells or organs.

The invention discloses a lipid composition for preparing extracellular vesicles, which is prepared from the following lipid substances in percentage by mass: 2 to 18 percent of phosphatidylcholine, 2 to 14 percent of phosphatidylethanolamine, 7 to 27 percent of sphingomyelin, 0.5 to 7 percent of ceramide, 1.5 to 2.5 percent of phosphatidylinositol, 30 to 70 percent of cholesterol and 5 to 8 percent of phosphatidylserine, the fatty acid carbon number of the lipid substance satisfies the following conditions: the fatty acid carbon number of phosphatidylcholine is 16-20, the fatty acid carbon number of phosphatidyl ethanolamine is 16-18, the fatty acid carbon number of sphingomyelin is 16-24, the fatty acid carbon number of ceramide is 16-24, the fatty acid carbon number of phosphatidylinositol is 16-20, the fatty acid carbon number of phosphatidylserine is 18-24, and the molar ratio of cholesterol to sphingomyelin is 4-7. The extracellular vesicles are prepared from the lipid composition and used for biomarkers or drug carriers, and efficient oral drug delivery is achieved.

Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol, glucosylcholesterol; and modified by (b) ionizable lipids. The present disclosure also includes a method for preparing a modified lipid composition, the method comprises reconstituting (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol and / or glucosylcholesterol in the presence of (b) ionizable lipids to produce the modified lipid composition, and loading one or more heterologous functional agents into the modified lipid composition.

Meltable compositions configured for oral use, the compositions including at least one cannabinoid or cannabimimetic, are provided. The compositions include one or more fillers, typically a sugar alcohol, and a lipid. A method of forming such compositions is also provided.

The present disclosure relates to a gel composition comprising water, a lipid component comprising at least one long chain fatty acid of C16 to C24 in length and at least on medium chain fatty acid of C6 to C12 in length, wherein said fatty acids are bound as acyl groups in glycerides in the lipid component, a carbohydrate, and a gelling agent. Also provided herein is a method of making the gel composition comprising providing the lipid component, providing water, a carbohydrate, and a gelling agent, mixing the water, the gelling agent, and the carbohydrate to form a mixture, and adding the lipid component into the mixture and homogenizing to form a gel composition. The gel compositions described herein may be useful as ergogenic aids.

Provided herein are methods and materials for using organisms (e.g., engineered yeast strain-derived) to generate lipid compositions which can modulate cellular aging, extend lifespan, and / or modulate gut homeostasis in a subject. The lipid compositions contain at least twelve of the lipids selected from a phosphatidylethanolamine (PE); a lysophosphatidylethanolamine (LPE); a diacylglycerol (DG); a monoglyceride (MG); an acyl carnitine (AcCa); a phosphatidic acid (PA); a phosphatidylglycerol (PG); a lysophosphatidylcholine (LPC); a triacylglycerol (TG); a cholesterol ester (ChE); a wax ester (WE); a phosphatidylserine (PS); a phosphatidylcholine (PC); a phosphatidylinositol (PI); a ceramide (Cer); and a lysophosphatidylserine (LPS).

Disclosed herein are aspects of a compound according to Formula (I) Y[-Z-Ao-X]y. The compound may have a structure according to Formula (II) or Formula (III). Also disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and / or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some aspects, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.

Provided are a lipid nanoparticle composition for delivering a nucleic acid drug, a preparation method therefor, and use thereof. The lipid nanoparticle composition comprises three lipid components: a steroid-cationic lipid compound, a neutral phospholipid, and a polyethylene glycol lipid. The composition prepared by mixing the described components has relatively good stability and transfection efficiency. The lipid nanoparticle is used for delivering nucleic acid, such as mRNA, can efficiently and stably deliver the nucleic acid drug to a target cell or organ, and can induce a relatively high specific antibody response in an experimental animal, and the antibody has a better safety profile.

The invention discloses a pharmaceutical composition for treating atopic dermatitis and a preparation method and application of the pharmaceutical composition for treating atopic dermatitis. The pharmaceutical composition comprises matrix vaseline, a humectant, a moistening agent, a repairing agent and an antioxidant. Two lipid components (gamma-linolenic acid and linoleic acid) are supplemented, so that eczema-like dermatitis can be obviously relieved, skin lesion inflammatory cell infiltration is reduced, the content of fatty acid in a skin barrier is recovered, treatment of atopic dermatitis is assisted, and the treatment effect on the atopic dermatitis is remarkable; the pharmaceutical composition disclosed by the invention has the advantages of quick effect on atopic dermatitis, small toxic and side effects, good safety and good medicinal prospect.

Lipid composition comprising: (i) one or more cationic lipids, preferably cationically ionizable lipids, (ii) one or more phospholipids, and (iii) one or more statistical copolymers comprising repeating units of the following formula (I-a) and repeating units of formula (II-a) wherein R1 represents a hydrogen atom or a group selected from a C1-3 alkyl group, a cyclopropyl group, and a C3 alkenyl group; R2 represents a group selected from a saturated C4-40 hydrocarbyl group; an unsaturated C4-40 hydrocarbyl group having one or more carbon-carbon double and / or triple bonds; a saturated C4-40 heterohydrocarbyl group containing 1 to 5 divalent groups selected from ether, thioether, sulfone, sulfoxide, keto, ester, amide, carbamate and carbonate groups, and / or 1 to 5 fluorine atoms as substituents; and an unsaturated C4-40 heterohydrocarbyl group having one or more carbon-carbon double and / or triple bonds, and containing 1 to 5 divalent groups selected from ether, keto, ester, and carbonate groups and / or 1 to 5 fluorine atoms as substituents; and x and y independently represent 0 or 1.

The present invention addresses the problem of providing: an agent for delivering a nucleic acid to immune cells, which is capable of delivering a nucleic acid to both activated immune cells and non-activated immune cells; and a method for delivering a nucleic acid to immune cells using the agent for delivering a nucleic acid to immune cells. The present invention provides an agent for delivering a nucleic acid to immune cells, the agent comprising a lipid composition comprising: an ionizable lipid that is a compound represented by formula (1) or a salt thereof; a non-ionizable lipid; a lipid having a nonionic polymer; and a nucleic acid. In the formula, R1 to R9 are as defined in the description.

The invention relates to a lipid composition, which comprises a polymer lipid, and the polymer lipid is a compound with a structure as shown in a formula (I), or a pharmaceutically acceptable salt, an isotope variant, a tautomer or a stereoisomer thereof. The invention also provides a nanoparticle composition and a pharmaceutical composition comprising the lipid composition, and an application of the lipid composition in delivery of a load. The polymer lipid compound in the lipid composition can replace PEG lipid and has the advantages of biocompatibility, easiness in decomposition in vivo and no toxicity, so that a novel lipid delivery system is obtained.

The invention relates to the field of synthetic biology, in particular to a structural lipid, a preparation method thereof, a structural lipid composition containing the structural lipid and used for protecting liver and eyes, and a product for protecting liver and eyes. The preparation method comprises the following steps: carrying out reaction on mixed oil and lipase, and carrying out enzyme deactivation to prepare structural lipid; wherein the weight ratio of omega3 fatty acid to omega6 fatty acid to omega9 fatty acid in the oil material is (0.8-1.2): (0.8-1.2): (0.8-1.2). The lipase is adopted to carry out hydrolysis reaction on appropriate oil, sn-2 site fatty acid with the liver and eye protection effect can be prepared, and the sn-2 site fatty acid is small in molecular weight and beneficial to absorption.

To provide a means effective in suppressing oxidative deterioration of fats and oils containing polyunsaturated fatty acid containing DHA and to provide a method capable of determining near olfactory sense of human being by specifying a component that becomes an index of oxidative deterioration of fat and acid containing DHA.SOLUTION: A lipid composition containing lipids composed of polyunsaturated fatty acids as constituent fatty acids, wherein a composition ratio of polyunsaturated fatty acids among all constituent fatty acids of the lipids is 15% or more, the moisture content is 600 ppm or less, perfluorooctanesulfonic acid is 0.1 ppb or less, and perfluorooctanoic acid is 0.1 ppb or less. It is preferable that the composition contains 2-(2-pentenyl)furan at less than 0.0095 ppm, and 2,4-heptadienal at less than 2.600 ppm.SELECTED DRAWING: None

Relates to a lipid composition with targeting property, the lipid composition comprises an active component, a lipid carrier and a targeting component, and the components of the lipid carrier comprise a positively charged component and phospholipid. An active component is entrapped in a lipid carrier containing a component with positive charges, so that the surface of the lipid carrier has positive charges, then the lipid carrier and a targeting component with negative charges are mixed, and the targeting component is adsorbed on the surface of the drug-loaded lipid carrier with positive charges through an electrostatic adsorption effect, so that the drug-loaded lipid carrier which is high in transfection efficiency and good in transfection effect is prepared. The present invention relates to a lipid composition having a targeting property and a high targeting property. The invention relates to a lipid nanoparticle delivery system with high biological activity, tumor targeting property and good safety. The lipid nanoparticle delivery system comprises an active component, cationic lipid, ionizable lipid and neutral phospholipid. The active component is entrapped in the lipid nanoparticle containing the cationic lipid, the ionizable lipid and the neutral phospholipid, and when the molar ratio of the cationic lipid to the ionizable lipid is in a specific range, the lipid nanoparticle has higher biological activity, tumor targeting property and good safety.

This application relates to the fields of chemistry and biomedicine, specifically to a tofenamic acid lipid composition, its preparation method, and its application. A tofenamic acid derivative is obtained by reacting a morpholine solution with tofenamic acid, ethyldimethylaminopropylcarbodiimide, and 4-dimethylaminopyridine, followed by purification. The morpholine in the morpholine solution is an N-alkylmorpholine compound. The tofenamic acid derivative is used to prepare tofenamic acid prodrug liposomes via ethanol injection, which are then used in combination with a STING agonist. The synergistic effect of the combined treatment stems from the dual regulation of the tumor immune microenvironment (TME), overcoming the immune escape induced by STING monotherapy. After STING agonist treatment, the intratumoral COX-2 / PGE2 axis is activated, leading to immunosuppression. The combination of tofenamic acid liposomes and a STING agonist inhibits COX-2, thus relieving this negative feedback loop.

Described herein are methods for making edible fat product using insect cells. The methods include isolating a population of insect cells, which may be precursor cells, seeding the population of insect cells onto a scaffold, and contacting the population of insect cells with a free fatty acid composition or a lipid composition. The cells seeded on the scaffold accumulate lipids, resulting in an edible fat tissue. Further disclosed are a composition of matter made from the method for making edible fat cells, a food product that includes the composition of matter, and an in vitro edible fat tissue comprising a population of insect precursor cells seeded on the scaffold.

The invention relates to a tobacco exosome as well as a preparation method and application thereof. The tobacco exosome comprises nicotine, lipid composition, a small molecule compound and protein, and in the tobacco exosome, the concentration of the nicotine is higher than 1 ng / mL. The tobacco exosome prepared by the invention can effectively inhibit inflammatory activity induced by microglial cells LPS, inhibit secretion of inflammatory factors PGE2 and transcriptional expression of iNOS, IL-1beta and IL-6. In a mouse neuroinflammation model experiment, the tobacco exosome prepared by the invention can improve behavioral changes of a mouse neuroinflammation model, and the improvement effect is better than that of other plant exosomes, such as potato exosomes.

The invention discloses a macrophage-targeting lipid nanoparticle and application thereof in malignant tumor treatment, ID3 mRNA is delivered through the lipid nanoparticle, firstly, an ID3 sequence is subjected to codon optimization to improve the expression efficiency and stability of ID3 protein, and the core treatment effect is enhanced; the lipid composition and the targeting ligand of the nanoparticles are further optimized, and mannose modified PEG lipid material (DSPE-PEG2000-Mannose) is specifically combined with the CD206 receptor on the surface of the macrophage, so that the targeting property and the transfection efficiency of the delivery system are remarkably improved. The ID3 mRNA is delivered to the macrophages by utilizing the lipid nanoparticles of the targeted macrophages, so that the tumor cells can be effectively swallowed and killed, the in-situ treatment of pancreatic cancer is realized, and better tumor inhibition and immune activation effects are achieved.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value..

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The present invention addresses the problem of providing: a compound or a salt thereof that is to constitute a lipid composition that makes it possible to achieve high expression of a protein when an mRNA is used and dose-responsive protein production when administered at a high dose; and a lipid composition, a pharmaceutical composition, and a delivery carrier that use the compound or salt thereof. The present invention provides a compound represented by formula (1) or a salt thereof. Each group in the formula is defined in the description.